

Accepted Manuscript

Novel treatments for idiopathic pulmonary fibrosis

Paolo Spagnolo, MD, PhD

PII: S0002-9343(15)00012-1

DOI: [10.1016/j.amjmed.2015.01.003](https://doi.org/10.1016/j.amjmed.2015.01.003)

Reference: AJM 12842

To appear in: *The American Journal of Medicine*

Received Date: 24 October 2014

Revised Date: 7 January 2015

Accepted Date: 8 January 2015

Please cite this article as: Spagnolo P, Novel treatments for idiopathic pulmonary fibrosis, *The American Journal of Medicine* (2015), doi: 10.1016/j.amjmed.2015.01.003.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Title page**Novel treatments for idiopathic pulmonary fibrosis**

Paolo Spagnolo MD, PhD

Medical University Clinic
Canton Hospital Baselland, and University of Basel
Rheinstrasse 26, 4410 Liestal, Switzerland
Tel. +41 (0)61 925 25 25
FAX +41 (0)61 925 28 04
E-mail: paolo.spagnolo@ksbl.ch

Funding source: none

Conflict of interest: Dr P Spagnolo serves as consultant for InterMune and has received consulting fees from Boehringer Ingelheim.

Article type: Commentary

Key words: idiopathic pulmonary fibrosis, treatment, clinical trials, nintedanib, pirfenidone.

Running head: Therapy of idiopathic pulmonary fibrosis.

Download English Version:

<https://daneshyari.com/en/article/5875719>

Download Persian Version:

<https://daneshyari.com/article/5875719>

[Daneshyari.com](https://daneshyari.com)